Chalcogen Or Nitrogen Bonded Directly At 1-, 3-, Or 5-position By Nonionic Bonding Patents (Class 514/390)
  • Patent number: 9884044
    Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 6, 2018
    Assignee: Lyotropic Therapeutics, Inc.
    Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
  • Patent number: 9636327
    Abstract: The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 2, 2017
    Assignee: University Health Network
    Inventor: Kumaraswamy Nanthakumar
  • Patent number: 9339492
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: May 17, 2016
    Assignee: Scioderm, Inc.
    Inventors: Elliott Farber, Robert Ryan
  • Patent number: 9248089
    Abstract: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 2, 2016
    Assignee: GRF (WUHAN) BIOTECHNOLOGY INC.
    Inventors: Feng Tian, Daniel Liang Zou, Lingyun Ji
  • Patent number: 9168311
    Abstract: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 27, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 9102645
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 11, 2015
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: Grace E. Stutzmann, Russell Dahl, Christopher H. Kaiho
  • Patent number: 9056209
    Abstract: Provided is a composition which maintains apigenin stably. The present invention provides the composition containing apigenin at 3 ppm or more and dibutylhydroxytoluene, wherein the mass ratio of the content of apigenin relative to the content of dibutylhydroxytoluene is 1 or greater, or the pH value is less than 7. Also provided is a method for preparing an apigenin-containing composition, the method including combining 3 ppm or more of apigenin with dibutylhydroxytoluene so that the mass ratio of the content of apigenin relative to the content of dibutylhydroxytoleune is 1 or greater, or including adjusting the ph of the composition to a value less than 7.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: June 16, 2015
    Assignee: Kao Corporation
    Inventors: Mitsuru Sugiyama, Shinya Kasamatsu
  • Publication number: 20150099009
    Abstract: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 9, 2015
    Inventors: George Rodeheaver, Adam Katz
  • Patent number: 8986746
    Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 24, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis
  • Patent number: 8986745
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 24, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 8974833
    Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 10, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 8916599
    Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 23, 2014
    Assignee: Orexo AB
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer, Juergen Mack, Henning Priepke, Dirk Stenkamp
  • Patent number: 8911791
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 16, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20140336120
    Abstract: A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition can include a compound which is a combination of dantrolene and a residue of FMOC-valine. This composition can be used to provide a faster and higher CNS penetration than heretofore experienced with dantrolene. In another form, dantrolene may be formulated as a pro-drug, a pro-pro-drug and the like.
    Type: Application
    Filed: May 8, 2014
    Publication date: November 13, 2014
    Applicant: Howard University
    Inventors: Harpal S. Mangat, Pradeep K. Karla
  • Publication number: 20140335069
    Abstract: Aspects of embodiments may include methods for automated enzymatic detection of glucose-6-phosphate dehydrogenase (G6PD) activity. Aspects of embodiments may include methods for enzymatic detection of G6PD activity in droplets in oil. Aspects of embodiments may include a system including a droplet actuator. Aspects of embodiments may include a treatment method.
    Type: Application
    Filed: November 20, 2012
    Publication date: November 13, 2014
    Applicant: ADVANCED LIQUID LOGIC, INC.
    Inventors: Carrie A. Graham, Allen E. Eckhardt
  • Patent number: 8877788
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: November 4, 2014
    Assignee: Scioderm, Inc.
    Inventor: Elliott Farber
  • Patent number: 8877790
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: November 4, 2014
    Assignee: Scioderm, Inc.
    Inventor: Elliott Farber
  • Patent number: 8877789
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: November 4, 2014
    Assignee: Scioderm, Inc.
    Inventor: Elliott Farber
  • Publication number: 20140288137
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 25, 2014
    Applicant: Scioderm, Inc.
    Inventors: Elliott FARBER, Robert RYAN
  • Publication number: 20140275112
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventors: Grace E. Stutzmann, Russell Dahl
  • Publication number: 20140275087
    Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying X. Wang, Hongyu H. Zhao, Huan-Qiu Li, Jason T. Brewer, Irini Zanze, Justin Dietrich, Anil Vasudevan, Stevan W. Djuric, Yanbin Lao, Charles W. Hutchins
  • Publication number: 20140256684
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Publication number: 20140256685
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath, Edward Hsia
  • Publication number: 20140228333
    Abstract: In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 6, 2012
    Publication date: August 14, 2014
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Christopher M. Adams, Steven D. Kunkel, Michael Welsh
  • Publication number: 20140206732
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 24, 2014
    Applicant: Scioderm, Inc.
    Inventor: Elliott Farber
  • Publication number: 20140194482
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Application
    Filed: January 3, 2014
    Publication date: July 10, 2014
    Inventors: Elliott FARBER, Robert Ryan
  • Publication number: 20140170246
    Abstract: A topical composition having at least one active agent selected from a depilatory agent(s), an agent(s) for preventing or reducing the growth or re-growth of hair and an agent(s) for preventing or reducing in-growing hair, and a gas, wherein the at least one active agent and gas are dispersed in a cosmetically acceptable medium.
    Type: Application
    Filed: February 20, 2014
    Publication date: June 19, 2014
    Inventors: Magali Bertrand, Philippe Henriat
  • Publication number: 20140162987
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: June 12, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 8748411
    Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: June 10, 2014
    Assignee: Centro de Ingenieria Genetica y Biotechnologia
    Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gómez
  • Publication number: 20140142151
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Application
    Filed: October 9, 2013
    Publication date: May 22, 2014
    Applicant: Scioderm, Inc.
    Inventor: Elliott Farber
  • Publication number: 20140135372
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 15, 2014
    Inventor: Elliott FARBER
  • Publication number: 20140135385
    Abstract: This invention relates to methods of treating T-cell mediated diseases or disorders in human or animal subjects, such as autoimmune diseases and chronic graft versus host disease in humans and animals. In particular, the methods comprise administering to the human or animal patient a pharmaceutical composition comprising a ryanodine receptor inhibitor.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Applicant: The Regents of the University of California
    Inventor: Alla F. Fomina
  • Publication number: 20140128353
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: Biocopea Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Publication number: 20140121255
    Abstract: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
    Type: Application
    Filed: October 24, 2013
    Publication date: May 1, 2014
    Applicant: Scioderm, Inc.
    Inventor: Elliott FARBER
  • Publication number: 20140099382
    Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
    Type: Application
    Filed: December 11, 2013
    Publication date: April 10, 2014
    Applicant: Lyotropic Therapeutics, Inc.
    Inventors: David Anderson, Benjamin G. Cameransi, JR., Vincent M. Conklin
  • Patent number: 8685466
    Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: April 1, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis
  • Patent number: 8664251
    Abstract: This invention relates to methods of treating T-cell mediated diseases or disorders in human or animal subjects, such as autoimmune diseases and chronic graft versus host disease in humans and animals. In particular, the methods comprise administering to the human or animal patient a pharmaceutical composition comprising a ryanodine receptor inhibitor.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: March 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Alla F. Fomina
  • Patent number: 8658219
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: February 25, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20140039019
    Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death.
    Type: Application
    Filed: October 7, 2013
    Publication date: February 6, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Cun-Jian Dong, William A. Hare
  • Patent number: 8637086
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: January 28, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 8632822
    Abstract: There is provided wound healing composition which comprises at least one oxidant, at least one photoactivator capable of actuating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: January 21, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20140010771
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Application
    Filed: September 4, 2013
    Publication date: January 9, 2014
    Applicant: Scioderm, Inc.
    Inventor: Elliott FARBER
  • Publication number: 20140005242
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Application
    Filed: September 4, 2013
    Publication date: January 2, 2014
    Applicant: Scioderm, Inc.
    Inventor: Elliott FARBER
  • Publication number: 20130345274
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Application
    Filed: July 15, 2013
    Publication date: December 26, 2013
    Inventor: Elliott Farber
  • Publication number: 20130338204
    Abstract: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 8536213
    Abstract: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: September 17, 2013
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 8450337
    Abstract: Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: May 28, 2013
    Assignee: Moleculin, LLC
    Inventors: Waldemar Priebe, Charles Conrad, Timothy Madden
  • Publication number: 20130123215
    Abstract: The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: November 9, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventor: Allergan, Inc.
  • Patent number: 8431607
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: April 30, 2013
    Assignee: IRM LLC, A Delaware Limited Liability Company
    Inventors: Hong Liu, Xiaohui He, Dean Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
  • Publication number: 20130096111
    Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.
    Type: Application
    Filed: September 17, 2012
    Publication date: April 18, 2013
    Applicant: The Board of Regents of The University of Texas System
    Inventor: The Board of Regents of The University of Texas S